Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbot Medical ( (MBOT) ) has shared an announcement.
On February 5, 2026, Microbot Medical announced its participation in the Society of Interventional Oncology annual meeting in Savannah, Georgia, held from February 4-8, 2026, where it is showcasing its LIBERTY Endovascular Robotic System during the product’s limited market release phase. The event marks the first commercial exhibition of LIBERTY since the limited launch began in late 2025, enabling the company to share real-world physician experiences across hospitals and procedure types, conduct hands-on live demonstrations for interventional oncologists, and build commercial awareness and adoption ahead of a planned full market release at the Society of Interventional Radiology conference in April 2026.
The most recent analyst rating on (MBOT) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. (Nasdaq: MBOT) is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the world’s first FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular procedures, designed to enhance precision, efficiency and safety while reducing radiation exposure and physical strain for clinicians.
Average Trading Volume: 1,899,999
Technical Sentiment Signal: Sell
Current Market Cap: $116.9M
See more insights into MBOT stock on TipRanks’ Stock Analysis page.